
PROTAK™ Lenalidomide (CC-5013)

E31P14976

Catalog Number: E31P14976-1, E31P14976-2
Product Name: PROTAK™ Lenalidomide (CC-5013)
Amount: 50mg,100mg
CAS No.: 191732-72-6
Name: 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
Molecular Structure:



Purity: >98.00%
Formula: C13H13N3O3
M.W.: 259.3
Solubility: ≥100.8 mg/mL in DMSO, <2.29 mg/mL in EtOH, <2.53 mg/mL in H2O
Storage/Stability: Store at -20° C
Background: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects. It has been extensively studied for the treatment of multiple myeloma and myelodysplastic syndrome as well as lymphoproliferative disorders including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. According to recent studies, Lnalidomide promotes and restores immune system function in CLL patients by inducing an overexpression of costimulatory molecules in leukemic lymphocytes to restore the humoral immunity and immunoglobulins production as well as improving the ability of T cells and leukemic cells to form synapses with T lymphocytes..

PROTAK™ is a registered trademark of EnoGene.

For Research Use Only